National Drug & Alcohol Research Centre Blog

NOVEMBER 12, 2023

Professor Shane Darke NDARC's Professor Shane Darke discusses the findings of a new study published in Addiction journal, which found that 610 people died from heroin overdose between 2020-22. In order to examine the situation regarding fatal heroin overdose in Australia in the early 2020s, we examined all cases over the period 2020 to 2022.

Treatment 52

Treatment Drugs 52

The Pharma Data

NOVEMBER 18, 2020

The 2020 updated HIV drug resistance strategy – which is to be released before the end of the year – considers lessons learned in the field over the last decade and anticipates the ongoing scale-up of antiretroviral therapy and HIV pre-exposure. Map of countries implementing national HIV drug resistance surveys, 2004–2020. .

Laboratories 52

Laboratories Therapies Virus Government 52

The Pharma Data

NOVEMBER 9, 2020

An experimental Alzheimer’s disease treatment should not be approved by the U.S. “If we approve something when the data is not strong, we have a risk of delaying good treatments and effective treatments for more than a couple of years, for many years,” Perlmutter said. © 2020 HealthDay. .

Pharmaceutical Companies 52

Pharmaceutical Companies Treatment FDA Disease 52

The Pharma Data

JANUARY 20, 2021

a medical device company focused on the development and commercialization of treatments focused on the development and commercialization of treatments for knee pain caused by osteoarthritis (OA), today announced its company highlights for 2020 which have exceeded revenue targets. . DOYLESTOWN, Pa. ,

Production 52

Production Treatment Compliance Licensing 52

Eye on FDA

MARCH 5, 2023

By contrast, already in 2023 there have been eight AdComm meetings scheduled by FDA for the purpose of considering a new medical treatment, three of which have occurred and all resulting in votes in favor of the sponsor, so perhaps 2023 is heading to less negative territory. There are a lot of variables that factor in.

FDA 72

FDA Vaccine Drugs Therapies 72

The Pharma Data

MAY 14, 2021

Product Name: Home – Beat Kidney Disease – 2020 – Beat Kidney Disease. Home – Beat Kidney Disease – 2020 – Beat Kidney Disease is backed with a 60 Day No Questions Asked Money Back Guarantee. Always consult your physician before beginning any treatment, diet, or exercise program.

Disease 52

Disease Production Licensing Licensing 52

The Pharma Data

NOVEMBER 30, 2020

The UK-based RECOVERY trial, which is evaluating multiple treatments for COVID-19, will add the inexpensive anti-inflammatory drug colchicine to the list of therapies being tested in hospitalized patients.

Treatment 52

Treatment Trials Hospitals Therapies 52

The Pharma Data

JANUARY 12, 2021

(NASDAQ: NARI) (“Inari”) a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2020 revenue. million to $48.9 About Inari Medical, Inc. Inari Medical, Inc.

FDA 52

FDA Treatment Production Disease 52

The Pharma Data

NOVEMBER 3, 2020

4, 2020 /PRNewswire/ — Q3 2020 highlights. Updated financial outlook 2020. 2020 Jul-Sep. 2020 Jan-Sep. 2019-2020 Jul-Sep ?. . Updated financial outlook 2020.

Therapies 52

Therapies Pharmaceuticals Production Marketing 52

The Pharma Data

NOVEMBER 8, 2020

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. LONDON and RALEIGH, N.C.,

Therapies 52

Therapies Treatment Disease Hospitals 52

The Pharma Data

DECEMBER 29, 2020

Primary Aldosteronism Testing Rare in Treatment-Resistant HTN. 29, 2020 — Patients with apparent treatment-resistant hypertension are rarely tested for primary aldosteronism, according to a study published online Dec. Veterans Health Administration with apparent treatment-resistant hypertension from 2000 to 2017.

Treatment 52

Treatment International Therapies Research 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of next generation drugs for the treatment of cancer. BUFFALO, N.Y., Founded in 2003, Athenex, Inc. For more information, please visit www.athenex.com.

Engineering 52

Engineering Therapies Treatment International 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. It began in May with the $4.9

Science 52

Science Disease Pharmaceuticals Treatment 52

The Pharma Data

OCTOBER 20, 2020

21, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. Eastern Time to discuss its third quarter 2020 financial results and report on pipeline and business progress. Webcast scheduled for Wednesday, November 4 at 11:30 a.m. Eastern Time. . CARLSBAD, Calif. , Interested parties may access the webcast at www.ionispharma.com.

RNA 52

RNA Pharmaceuticals Disease Treatment 52

The Pharma Data

DECEMBER 31, 2020

Monthly News Roundup – December 2020. In the Phase 3 HERO study , treatment with Orgovyx led to sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in 96.7% Orladeyo should not be used for the treatment of acute HAE attacks. Professional. In December, the U.S.

FDA Approval 52

FDA Approval Vaccine FDA Treatment 52

The Pharma Data

NOVEMBER 25, 2020

AHA: Ablation Better Than Meds for Initial A-Fib Treatment. 25, 2020 — Cryoballoon ablation is superior to drug therapy as an initial treatment for the prevention of atrial arrhythmia recurrence in patients with paroxysmal atrial fibrillation , according to a study published online Nov. © 2020 HealthDay. Wazni, M.D.,

Treatment 52

Treatment Therapies Disease Drugs 52

The Pharma Data

DECEMBER 8, 2020

Johnson & Johnson subsidiary Janssen has unveiled longer-term results from its phase 1b/2 study of ciltacabtagene autoleucel (cilta-cel) showing the drug, which is being studied as a treatment for patients with relapsed and/or refractory multiple myeloma, kept a large number of participants alive and progression-free. Source link.

Treatment 40

Treatment Clinical Research Trials Research 40

The Pharma Data

NOVEMBER 10, 2020

Antibody Treatment Approved for Emergency Use Against Early COVID-19. 10, 2020 — Eli Lilly’s experimental antibody treatment for COVID-19 was given emergency approval by the U.S. Instead, the treatment should be given as soon as possible after a positive test and within 10 days of developing symptoms.

Treatment 52

Treatment Government Hospitals FDA 52

The Pharma Data

DECEMBER 28, 2020

Triple Treatment Combo Beneficial in BRAF-Mutant CRC. 28, 2020 — Irinotecan and cetuximab combined with vemurafenib improve progression-free survival in BRAF V600E -mutated colorectal cancer (CRC), according to a study published online Dec. © 2020 HealthDay. Posted: December 2020. Professional. MONDAY, Dec.

Treatment 52

Treatment RNA DNA Disease 52

The Pharma Data

DECEMBER 17, 2020

18, 2020 /PRNewswire/ — Camurus AB (NASDAQ STO: CAMX) announced today that the Swiss agency for therapeutic products, Swissmedic, has approved weekly and monthly Buvidal ® prolonged release buprenorphine for the treatment of opioid dependence in adults and adolescents from 16 years of age. LUND, Sweden , Dec. About Buvidal.

Treatment 52

Treatment Clinical Trials International Pharmaceutical Companies 52

The Pharma Data

DECEMBER 30, 2020

The Feverish Pricing of MS Treatments. Towards the end of March, the FDA approved two new treatments for multiple sclerosis (MS): Mayzent (siponimod) and Mavenclad (cladribine). Drug treatments for MS have been climbing an expensive staircase for a number of years. Posted: December 2020. Consumer News. Source link.

Treatment 52

Treatment FDA Approval Disease FDA 52

National Institute on Drug Abuse: Nora's Blog

FEBRUARY 8, 2023

Pregnant People With Substance Use Disorders Need Treatment, Not Criminalization mfleming Wed, 02/08/2023 - 15:33 Nora's Blog February 15, 2023 Image ©Getty Images/ Caia Image This blog was also published in STAT on February 8, 2023. People seeking treatment for addictions face additional obstacles, especially if they have children.

Treatment 52

Treatment Doctors Research Science 52

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — Summary. Financial overview July 1 – September 30, 2020. Significant events during the period July 1 – September 30, 2020. 2020 Jul – Sep. 2020 Jan – Sep. STOCKHOLM , Nov. M (0.0).

FDA 40

FDA Pharmaceutical Companies Marketing Treatment 40

The Pharma Data

AUGUST 6, 2020

NEW YORK–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. billion, as of June 30, 2020. June 30, 2020 on. Second Quarter. . . Total Revenues.

Production 52

Production International Licensing Licensing 52

The Pharma Data

SEPTEMBER 24, 2020

NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328 th consecutive quarterly dividend paid by Pfizer. Pfizer Inc.:

Government 40

Government Vaccine Science Therapies 40

The Pharma Data

DECEMBER 15, 2020

Less Invasive Treatment Feasible for Early-Stage Rectal Cancer. 15, 2020 — Short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC) achieves a high level of organ preservation and improved quality of life, according to a study published online Dec. © 2020 HealthDay.

Treatment 52

Treatment Clinical Trials Pharmaceuticals Trials 52

The Pharma Data

NOVEMBER 23, 2020

FDA Authorizes Use of Monoclonal Antibody Treatment for COVID-19. 23, 2020 — A combination of two monoclonal antibodies was granted emergency use authorization (EUA) for the treatment of mild-to-moderate COVID-19, the U.S. © 2020 HealthDay. Posted: November 2020. Professional. MONDAY, Nov. More Information.

FDA 52

FDA Treatment Hospitals Clinical Trials 52

The Pharma Data

OCTOBER 22, 2020

CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy. Source link.

Treatment 40

Treatment Therapies Trials Pharmaceuticals 40

Drugs.com

MAY 15, 2024

cancer death rates are continuing to drop, falling by 33% between 1991 and 2020.However, However, not all Americans are reaping the benefits from advances in cancer prevention, early detection and treatment, a new report from. WEDNESDAY, May 15, 2024 -- U.S.

Treatment 98

Treatment 98

The Pharma Data

NOVEMBER 30, 2020

30, 2020 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. NASDAQ: REGN) will host a webcast on Monday, December 7, 2020 at 4:30pm EST. Management will discuss data presented at the American Society of Hematology (ASH) 2020 Annual Meeting as well as provide updates on the Company’s broader oncology and hematology portfolio.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

The Pharma Data

MARCH 9, 2022

Few treatments currently exist for COVID-19 and the ones that do primarily focus solely on preventing the virus from replicating. This new potential treatment inhibits replication but also protects or repairs tissue, which is important because COVID-19 can cause symptoms that affect patients long after the viral infection has been cleared.

Treatment 52

Treatment Virus Engineering Therapies 52

The Pharma Data

SEPTEMBER 1, 2020

Daiichi Sankyo has unveiled promising new benefit for Nilemdo (bempedoic acid) at the ESC Congress 2020 over the weekend for the management of low-density lipoprotein cholesterol (LDL-C) when added to other standards of care. Therefore, it is important to know how people respond to treatment over longer-term time periods.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

The Pharma Data

JANUARY 12, 2021

Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the full year 2020 is expected to be approximately $125.4 2020 was a transformational year for Vapotherm. Preliminary revenue for the full year 2020 is expected to be approximately $125.4

Therapies 52

Therapies Production Marketing Regulations 52

The Pharma Data

FEBRUARY 8, 2021

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer. ERLEADA ® is an androgen receptor (AR) inhibitor indicated for the treatment of patients with nmCRPC and for the treatment of patients with mCSPC. 10 months. [5]

Treatment 52

Treatment Pharmaceutical Companies Therapies Pharmaceuticals 52

The Pharma Data

OCTOBER 26, 2020

27, 2020 /PRNewswire/ — Synlogic, Inc. Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its third quarter 2020 financial results before the market opens on Thursday, November 5, 2020. CAMBRIDGE, Mass. ,

Clinical Trials 52

Clinical Trials Clinical Development Trials Engineering 52

Drug Target Review

JULY 1, 2024

As a non-opioid, SRP-001 also eliminates abuse potential, positioning it as a safer and effective drug candidate for the treatment of acute and neuropathic pain and migraine headache. How does SRP-001’s safety profile, especially concerning hepatotoxicity and nephrotoxicity, compare to other common pain medications?

Treatment 59

Treatment Clinical Trials Therapies Molecular Biology 59

The Pharma Data

MAY 16, 2021

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Merck’s Keytruda (pembrolizumab) for National Health Service use as first-line treatment for adults with untreated metastatic colorectal cancers with high levels of microsatellite instability or DNA mismatch repair deficiency. billion in 2020.

Treatment 52

Treatment DNA Drugs 52